Speaker
Description
Abstract- Due to limitation of drugs to fight against the COVID-19 disease, we found a procedure that allows the application in more advanced stages since there is currently no treatment protocol that achieves clinical containment of the disease. (DTAF), is associated with cancer treatment but has been adapted to COVID 19 at the pulmonary level due to the congruence and correlation with hypoxia conditions present in both nodular and microscopic neoplastic cells in association with COVID19 staging related to the formation of Frosted Glass at the deep alveolar interstitial level, which produce micro thrombosis formations and/or interstitial lesions with production of mucus and clots with severe inflammation that cause hypoxemia and drastic reduction in Oxygen Saturation and lead to death in patients affected. We propose and applied this method in Peru to discriminate the effectiveness in a reduced sample of patients,
Selective Tissue Sensitizer by RF has been developed that produce thermal gradients and increasing the perfusion and reduction of dense fluid accumulatios in the areas that present injury generating drug reabsorption and stimulating the virus inhibition process by modulation of the immune system at extracellular levels allowing the healing and reoxygenation of damaged areas.. We´ll show the cases report.
